Journal of the American Academy of Dermatology
Epstein-Barr virus–associated lymphoproliferative disease after long-standing cyclosporine therapy for psoriasis: A case of spontaneous regression
Section snippets
Case report
A 52-year-old white man was enrolled in 1986 in a cyclosporine therapy trial for psoriasis vulgaris. Methotrexate has been given before for 6 months but was discontinued because of the occurrence of hepatic side effects. Cyclosporine given at the level of 3 mg/kg/d resulted in a complete disappearance of dermatologic lesions. He was referred to our hospital in May 2001 for a 3-week fever with sweats, marked asthenia, and weight loss. Physical examination disclosed splenomegaly and axillary,
Results
The histologic examination of the lymph node biopsy specimen disclosed an effacement of the nodal architecture (Fig 1, A) by a polymorphic population of lymphoid cells consisting of atypical medium lymphocytes with plasmocytic differentiation admixed with scattered large cells displaying immunoblastic characteristics, a few plasmocytes, and small lymphocytes (Fig 1, B). Mitosis and apoptotic figures were numerous. Immunohistochemistry revealed the B-cell phenotype of the atypical medium cells
Discussion
EBV is associated with Hodgkin's disease, especially in patients with HIV infection, and non-Hodgkin's lymphomas.3 It is, however, also associated with a spectrum of lymphoproliferative disorders in patients with congenital, acquired (namely HIV infection), or iatrogenic immunodeficiencies especially in transplant recipients.4 The association between EBV infection and lymphoproliferative disorders in transplant recipients—posttransplant lymphoproliferative disorders (PTLD)—was first noted in
Conclusion
To our knowledge regressive EBV-associated lymphoproliferative disorders with aggressive presentation during low-dose cyclosporine therapy given for psoriasis has not been described before. Our observation emphasizes two points. First, the 15-year delay between treatment initiation, and the occurrence of lymphoproliferation observed in our patient, suggests that low-dose cyclosporine treatment entails a risk of PTLD that persists as long as the immunosuppressive drug is given. Second, although
References (20)
- et al.
Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy
Lancet
(1984) - et al.
Epstein-Barr virus nuclear antigen positive lymphoma after cyclosporin A treatment in patients with renal allograft
Lancet
(1980) - et al.
Epstein-Barr virus associated polymorphic lymphoproliferative disorders occurring in nontransplant settings
Lab Invest
(2001) - et al.
The development of B-cell lymphoma in a patient with psoriasis treated with cyclosporine
J Am Acad Dermatol
(1992) - et al.
Cutaneous T-cell infiltrates: analysis of T-cell receptor gamma gene rearrangement by polymerase chain reaction and denaturing gradient gel electrophoresis
Blood
(1995) - et al.
Low-dose cyclosporine A in severe psoriasis: a double-blind study
Br J Dermatol
(1988) - et al.
Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center
J Clin Oncol
(1995) - et al.
Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression
Transplantation
(1999) - et al.
Reversible lymphomas associated with Epstein-Barr virus occurrence during methotrexate therapy for rheumatoid arthritis and dermatomyositis
N Engl J Med
(1993)
Cited by (0)
This supplement is made possible through the generous support of Stiefel Laboratories for the American Academy of Dermatology.
Funding sources: None.
Conflicts of interest: None identified.